Stephen C. Hyde

8.7k total citations · 3 hit papers
114 papers, 5.8k citations indexed

About

Stephen C. Hyde is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Molecular Biology. According to data from OpenAlex, Stephen C. Hyde has authored 114 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Pulmonary and Respiratory Medicine, 43 papers in Genetics and 41 papers in Molecular Biology. Recurrent topics in Stephen C. Hyde's work include Cystic Fibrosis Research Advances (36 papers), Virus-based gene therapy research (35 papers) and RNA Interference and Gene Delivery (30 papers). Stephen C. Hyde is often cited by papers focused on Cystic Fibrosis Research Advances (36 papers), Virus-based gene therapy research (35 papers) and RNA Interference and Gene Delivery (30 papers). Stephen C. Hyde collaborates with scholars based in United Kingdom, United States and France. Stephen C. Hyde's co-authors include Deborah R. Gill, Christopher F. Higgins, Francisco V. Sepúlveda, Miguel A. Valverde, Uzi Gileadi, C. F. Higgins, Stephen R. Pearce, Maurice P. Gallagher, Michael J. Hartshorn and Paul Emsley and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Stephen C. Hyde

111 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Structural model of ATP-binding proteing associated with cystic fibrosis, multidrug resistance and bacterial transport

1990 957 citations Stephen C. Hyde, Deborah R. Gill et al. profile →
Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein

1992 492 citations Deborah R. Gill, Stephen C. Hyde et al. profile →
Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy

1993 301 citations Stephen C. Hyde, Deborah R. Gill et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen C. Hyde United Kingdom	34	3.0k	1.7k	1.4k	1.3k	612	114	5.8k
Deborah R. Gill United Kingdom	35	3.5k 1.2×	1.4k 0.9×	1.6k 1.2×	1.5k 1.2×	678 1.1×	119	6.3k
Pamela L. Zeitlin United States	50	3.8k 1.3×	5.1k 3.1×	1.7k 1.2×	462 0.4×	556 0.9×	142	9.2k
Michael Koval United States	55	4.5k 1.5×	1.1k 0.7×	496 0.4×	459 0.4×	326 0.5×	158	8.1k
Ann Harris United States	41	3.0k 1.0×	2.4k 1.4×	808 0.6×	395 0.3×	116 0.2×	180	5.6k
Norbert Kartner Canada	33	4.0k 1.3×	2.9k 1.8×	365 0.3×	3.2k 2.5×	482 0.8×	49	7.7k
Xingnan Li United States	34	1.9k 0.6×	1.1k 0.6×	729 0.5×	1.3k 1.0×	174 0.3×	92	5.4k
Zbyszko Grzelczak Canada	14	2.2k 0.7×	4.6k 2.7×	766 0.6×	502 0.4×	137 0.2×	18	6.5k
Randall J. Mrsny United States	45	3.1k 1.0×	606 0.4×	414 0.3×	687 0.5×	256 0.4×	123	6.8k
Ying-Tsong Chen Taiwan	30	3.2k 1.1×	536 0.3×	839 0.6×	405 0.3×	325 0.5×	60	8.3k
Farzin Farzaneh United Kingdom	45	4.4k 1.5×	295 0.2×	1.0k 0.7×	1.7k 1.3×	389 0.6×	215	9.6k

Countries citing papers authored by Stephen C. Hyde

Since Specialization

Citations

This map shows the geographic impact of Stephen C. Hyde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen C. Hyde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen C. Hyde more than expected).

Fields of papers citing papers by Stephen C. Hyde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen C. Hyde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen C. Hyde. The network helps show where Stephen C. Hyde may publish in the future.

Co-authorship network of co-authors of Stephen C. Hyde

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen C. Hyde. A scholar is included among the top collaborators of Stephen C. Hyde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen C. Hyde. Stephen C. Hyde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Davies, Jane C., Marcus Mall, Deepika Polineni, et al.. (2024). P045 Lenticlair™ 1: A phase 1/2 trial evaluating the safety, tolerability and efficacy of an inhaled F/HN-pseudotyped lentiviral vector for CF gene therapy in people with CF ineligible for CFTR modulators. Journal of Cystic Fibrosis. 23. S80–S80.

Davies, Jane C., Deepika Polineni, A. Christopher Boyd, et al.. (2024). Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial. American Journal of Respiratory and Critical Care Medicine. 210(12). 1398–1408. 9 indexed citations

Griesenbach, Uta, Gerry McLachlan, Cédric Cheminay, et al.. (2023). WS17.06 F/HN pseudotyped lentiviral vector-mediated transduction of non-human primates. Journal of Cystic Fibrosis. 22. S33–S33. 1 indexed citations

McLachlan, Gerry, Eric W.F.W. Alton, Alan Boyd, et al.. (2022). Progress in Respiratory Gene Therapy. Human Gene Therapy. 33(17-18). 893–912. 17 indexed citations

Gall, Tony Le, Mathieu Berchel, Lee Davies, et al.. (2021). Aerosol-Mediated Non-Viral Lung Gene Therapy: The Potential of Aminoglycoside-Based Cationic Liposomes. Pharmaceutics. 14(1). 25–25. 7 indexed citations

Munis, Altar M., Benjamin Wright, Frederic Jackson, et al.. (2021). RNA-seq analysis of the human surfactant air-liquid interface culture reveals alveolar type II cell-like transcriptome. Molecular Therapy — Methods & Clinical Development. 24. 62–70. 5 indexed citations

Zambrano, Alberto, et al.. (2020). Identification of AAV serotypes for lung gene therapy in human embryonic stem cell-derived lung organoids. Stem Cell Research & Therapy. 11(1). 448–448. 28 indexed citations

Tan, Tiong Kit, et al.. (2020). Lung-targeting lentiviral vector for passive immunisation against influenza. Thorax. 75(12). 1112–1115. 6 indexed citations

Alton, Eric W.F.W., Alan Boyd, Jane C. Davies, et al.. (2016). Genetic medicines for CF: Hype versus reality. Pediatric Pulmonology. 51(S44). S5–S17. 36 indexed citations

10.

Alton, Eric W.F.W., Alan Boyd, David J. Porteous, et al.. (2015). A Phase I/IIa Safety and Efficacy Study of Nebulized Liposome-mediated Gene Therapy for Cystic Fibrosis Supports a Multidose Trial. American Journal of Respiratory and Critical Care Medicine. 192(11). 1389–1392. 40 indexed citations

11.

Alton, Eric W.F.W., Alan Boyd, Jane C. Davies, et al.. (2014). LARGE-SCALE PRODUCTION OF LENTIVIRAL VECTORS FOR CF LUNG GENE THERAPY. Pediatric Pulmonology. 49. 293–293. 1 indexed citations

12.

Davies, Lee A., G. Nunez-Alonso, Gerry McLachlan, Stephen C. Hyde, & Deborah R. Gill. (2014). Aerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapy. 776275620–776275620. 3 indexed citations

13.

Alton, Eric W.F.W., A. Christopher Boyd, Shou‐Hsia Cheng, et al.. (2013). A PHASE 2B DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NON-VIRAL MEDIATED GENE THERAPY FOR CF. Oxford University Research Archive (ORA) (University of Oxford). 2 indexed citations

14.

Griesenbach, Uta, Makoto Inoue, Cuixiang Meng, et al.. (2012). Assessment of F/HN-Pseudotyped Lentivirus as a Clinically Relevant Vector for Lung Gene Therapy. American Journal of Respiratory and Critical Care Medicine. 186(9). 846–856. 79 indexed citations

15.

Alton, Eric W.F.W., Steve Cunningham, Jane C. Davies, et al.. (2010). LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS; THE RUN-IN STUDY. Pediatric Pulmonology. 298–298.

16.

Davies, Jane C., Geraint Davies, Stephen C. Hyde, et al.. (2009). EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CYSTIC FIBROSIS: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY''. Thorax. 64. 2 indexed citations

17.

Munkonge, Felix M., Vaksha Amin, Stephen C. Hyde, et al.. (2009). Identification and Functional Characterization of Cytoplasmic Determinants of Plasmid DNA Nuclear Import. Journal of Biological Chemistry. 284(39). 26978–26987. 32 indexed citations

18.

Horsley, Alex, Kenneth G. MacLeod, Charles Saunders, et al.. (2007). UKCF gene therapy consortium tracking study: Lung clearance index improves with treatment of an infective exacerbation. Pediatric Pulmonology. 335–336. 2 indexed citations

19.

Hyde, Stephen C., et al.. (2007). ENaC knockdown in the mouse lung using RNAi. Pediatric Pulmonology. 306–307. 1 indexed citations

20.

Equi, A, Jane C. Davies, Hazel Painter, et al.. (2005). Exploring the mechanisms of macrolides in cystic fibrosis. Respiratory Medicine. 100(4). 687–697. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact